Trial Profile
Phase I Study of Radium-223 and Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Metastases
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Radium 223 chloride (Primary) ; Pazopanib; Sorafenib
- Indications Bone metastases; Renal cell carcinoma
- Focus Biomarker; Pharmacodynamics
- 03 Mar 2020 Status changed from active, no longer recruiting to completed.
- 10 Dec 2019 Planned End Date changed from 1 Dec 2019 to 1 Feb 2021.
- 14 Feb 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.